Patient description: A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Visceral Leishmaniasis Male and female patients aged between 18 to 65 years (both inclusive) Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration, weight loss and splenomegaly) Presence of amastigotes (Leishmania Donovani bodies) at screening detected by rK39 dipstick test Female subjects of childbearing potential must have a negative serum pregnancy test at enrolment and be willing to use a reliable method of birth control, i.e. barrier method, intrauterine device, or tubal ligation Ability to comply with all study requirements Patients with Hb ≥ 6.0 g/dl Patients with platelets count ≥ 60,000/mm3 Patients should be immunocompetent (e.g., white blood cell count ≥ 2500/ mm3) Patients and/ or LAR must be give written informed consent Patients with clinically acceptable results from all the screening laboratory parameters and investigations  Known allergy or hypersensitivity reactions to any components of conventional or liposomal Amphotericin B formulations Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up Pregnant or lactating women Patients requiring dose adjustment during the study Serum creatinine concentration greater than twice the upper limit of normal (ULN), AST or ALT value greater than 10 times the ULN Patients who are required to be on concomitant therapy with IV fat emulsions, such as total parental nutrition (TPN) Patients with total bilirubin levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl) Patient with clinically significant Hematopoietic, renal, hepatic and electrolyte disorders (Low level of Magnesium and potassium) will be excluded as per the discretion of Investigator Patients with Clinically significant screening laboratory parameters in the opinion of the investigator Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent